If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi ® (glucagon) nasal powder
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can both Baqsimi™ (glucagon) nasal powder and glucagon for injection be used in a single hypoglycemic event?
There have been no studies conducted on the use of both Baqsimi and glucagon for injection to treat a single, severe hypoglycemic event
Use of Both Baqsimi and Glucagon for Injection
The recommended dose of Baqsimi is 3 mg administered as one actuation of the intranasal device into one nostril.1
Call for emergency assistance immediately after administering the dose.1
If there has been no response after 15 minutes, an additional 3 mg dose of Baqsimi from a new device may be administered while waiting for emergency assistance.1
There have been no studies conducted on the administration of Baqsimi and glucagon for injection, either Baqsimi followed by glucagon for injection or glucagon for injection followed by Baqsimi, to treat a single, severe hypoglycemic event. Thus, Eli Lilly and Company has no information on this usage of Baqsimi and glucagon for injection.2
Enclosed Prescribing Information
1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: February 11, 2022